---
title: "Ultragenyx projects $640M-$670M in 2025 revenue growth driven by product launches"
date: "2025-02-14 05:54:04"
summary: "Earnings Call Insights: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Management View CEO Emil Kakkis highlighted 2024 as a pivotal year, with progress in six late-stage programs and a 29% revenue growth over 2023. He confirmed exceeding the upper end of revenue guidance and announced expectations for two BLA submissions in..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Earnings Call Insights: Ultragenyx Pharmaceutical Inc. (NASDAQ:[RARE](https://seekingalpha.com/symbol/RARE "Ultragenyx Pharmaceutical Inc.")) Q4 2024

### Management View

* CEO Emil Kakkis highlighted 2024 as a pivotal year, with progress in six late-stage programs and a 29% revenue growth over 2023. He confirmed exceeding the upper end of revenue guidance and announced expectations for two BLA submissions in 2025 for Sanfilippo syndrome Type A and GSDIa. If approved, this would bring the company to six commercial products.
* International growth was emphasized, with successful launches of EVKEEZA in Europe, Canada, and Japan, and expanded access for other commercial therapies in Latin America, Canada, and Turkey. CEO Kakkis stated, "This progress sets us firmly on a path toward full year GAAP profitability in 2027."
* Chief Commercial Officer Erik Harris detailed strong performance across the commercial portfolio, with CRYSVITA generating approximately 290 start forms in Latin America, leading to 250 patients on reimbursed therapy. DOJOLVI added 120 start forms in the U.S., and EVKEEZA treated approximately 190 patients across 14 countries.
* CFO Howard Horn reported $560M in total revenue for 2024 and outlined revenue guidance for 2025 between $640M and $670M, representing 14%-20% growth. CRYSVITA is expected to contribute $460M-$480M, while DOJOLVI projections range from $90M-$100M.

### Outlook

* Ultragenyx expects continued global revenue growth in 2025, underpinned by the expansion of existing therapies and the anticipated commercialization of new products such as UX111 and DTX401.
* Revenue guidance for 2025 is set at $640M-$670M, with CRYSVITA projected to grow 12%-17% and DOJOLVI by 2%-14%.
* Management reiterated its focus on expense management and achieving full-year GAAP profitability by 2027.

### Financial Results

* Total revenue for Q4 2024 reached $560M, a 29% increase from 2023. CRYSVITA contributed $410M, DOJOLVI $88M, EVKEEZA $32M, and MEPSEVII $30M.
* Operating expenses totaled $1.1B, including $698M in R&D and $322M in SG&A. Net loss for 2024 was $569M or ($6.29) per share, with $745M in cash, cash equivalents, and marketable securities as of December 31, 2024.
* Analysts estimated Q4 revenue at $158.7M and EPS at ($1.27). Ultragenyx reported $560M for the full year but did not provide explicit Q4 adjusted EPS.

### Q&A

* Tazeen Ahmad, Bank of America: Questioned the confidence level in UX143's second interim readout. CEO Kakkis expressed stronger confidence due to a 0.01 p-value threshold and 12 months of data but noted the trial would proceed to a final analysis if needed.
* Salveen Richter, Goldman Sachs: Asked about the risks if the second interim fails. CEO Kakkis indicated variability in fracture rates as a potential factor but affirmed high confidence in the trial's eventual success.
* Yaron Werber, TD Cowen: Inquired about manufacturing readiness and commercialization for UX111. CEO Kakkis outlined plans for proactive engagement with payers and readiness to launch in critical treatment centers.

### Sentiment Analysis

* Analysts expressed cautious optimism, with recurring questions about UX143's fracture rate data and timing of interim analyses reflecting interest in clinical outcomes and potential delays.
* Management maintained a confident tone, emphasizing strong progress in clinical and commercial execution. Phrases like "we are set for a strong year of value creation" and "we feel very good about how Phase 3 conduct is going" showcased their confidence.
* Compared to the previous quarter, both analysts and management showed heightened focus on UX143 and its pivotal Phase 3 data.

### Quarter-over-Quarter Comparison

* Guidance for 2025 revenue increased to $640M-$670M, up from $530M-$550M in 2024. CRYSVITA's expected growth was revised to 12%-17% from prior projections.
* Management's tone remained optimistic, with more emphasis on key clinical milestones such as UX143 interim analyses and UX111 BLA acceptance.
* Analysts maintained a similar level of interest in clinical trial progress and commercialization strategies. However, there was more detailed discussion regarding timing and outcomes of interim analyses.

### Risks and Concerns

* Variability in fracture rates was highlighted as a potential risk for interim analyses in UX143 trials. Management emphasized confidence but acknowledged possible delays.
* Analysts raised concerns about manufacturing scale-up and operational readiness for UX111's first gene therapy launch.
* Cost management and net cash use remain a critical focus, with operating expenses of $1.1B in 2024.

### Final Takeaway

Ultragenyx delivered strong revenue growth in 2024 and raised its guidance for 2025, signaling confidence in its expanding product portfolio. Key milestones, including UX111's BLA acceptance and UX143's Phase 3 interim readouts, are expected to drive further momentum. Management reaffirmed its path toward GAAP profitability by 2027, while addressing operational risks and maintaining focus on expense management. Investors will closely monitor clinical trial outcomes and the execution of upcoming product launches.

[Read the full Earnings Call Transcript](https://seekingalpha.com/symbol/RARE/earnings/transcripts)

[seekalpha](https://seekingalpha.com/news/4408340-ultragenyx-projects-640m-670m-in-2025-revenue-growth-driven-by-product-launches)
